Academic literature on the topic 'Canadian Committee for the International Biological Programme'

In 1994, the Canadian Standards Association (CSA) was asked by a coalition of twenty-three Canadian forest industry associations to undertake development of standards for Sustainable Forest Management (SFM). CSA agreed with the proposal and, for this purpose, formed a Technical Committee with representation from a wide variety of interested parties, including producers, woodlot owners, professionals and scientists, public and environmental groups, and governments. The open process, which was entirely that of CSA, was completed in two years, with the draft standards being approved by the Standards Council of Canada (SCC) as National Standards of Canada in September 1996. Verification that the standards have been achieved is accomplished through an independent audit conducted by a Registrar (certifying organization) accredited by the SCC. Certification is voluntary.The Standards framework consists of an environmental management system which is consistent with that of ISO 14001; however, requirements also include a public participation component, field performance measures, and the use of national SFM Criteria and Indicators developed by the Canadian Council of Forest Ministers, which in turn are based on results of the international Montreal process.

<p><br />In the recent past, a dramatic shift has been observed in the strategies of warfare from conventional to non-conventional. Now-a-days, traditional power is of less importance than it used to be earlier. Weapons of mass destruction, which comprise of nuclear weapons, and chemical and biological warfare agents, are posing a great peril to the world due to their devastating potential. Though, there are several bilateral as well as multilateral treaties to control the use and proliferation of these weapons, yet the risk of use of such agents by non-state actors cannot be overlooked. Chances of use of chemical and biological agents are more likely than the nuclear weapons. A comparison of nuclear, chemical and biological weapons in terms of technology, cost, signature, effectiveness on protected and un-protected troops shows that chemical and biological weapon programmes require much lower level of technology and cost than the nuclear weapon programme. Further, there is no or least distinctive and readily observable signature in biological weapon programme in comparison to nuclear and chemical weapon facilities. There can be two possibilities of use of these agents in terrorist attacks. First, there is a risk of transfer of material or know-how of these weapons to terrorists for using against the adversaries and second, the risk of these agents being pilfered due to poor security, thereby sabotaging the national security. The International Committee of Red Cross in February 1918 reckoned these agents as ‘barbarous inventions’ that can ‘only be called criminal’.</p>

IntroductionStress and obesity are two public health issues. The relationship between obesity and stress is biological through the actions of stress on the major hormones that regulate appetite (leptin and ghrelin). Many spa resorts in France specialise in the treatment of obesity, but no thermal spa currently proposes a specific programme to manage stress in obesity. The ObesiStress protocol has been designed to offer a new residential stress management programme. This thermal spa treatment of obesity implements stress management strategies as suggested by international recommendations.Methods and analysis140 overweight or obese participants with a Body Mass Index of >25 kg/m2 and aged over 18 years will be recruited. Participants will be randomised into two groups: a control group of usual practice (restrictive diet, physical activity and thermal spa treatment) and an intervention group with stress management in addition to the usual practice. In the present protocol, parameters will be measured on five occasions (at inclusion, at the beginning of the spa (day 0), at the end of the spa (day 21), and at 6 and 12 months). The study will assess the participants’ heart rate variability, cardiac remodelling and function, electrodermal activity, blood markers, anthropometric profile, body composition, psychology and quality of life via the use of questionnaires and bone parameters.Ethics and disseminationThe ObesiStress protocol complies with the ethics guidelines for Clinical Research and has been approved by the ethics committee (CPP Sud-Est VI, Clermont-Ferrand - ANSM: 2016-A01774-47). This study aimed to highlight the efficacy of a 21-day thermal spa residential programme of stress management in obesity through objective measurements of well-being and cardiovascular morbidity. Results will be disseminated during several research conferences and articles published in peer-reviewed journals.Trial registration numberNCT03578757.

IntroductionPatients with cancer often suffer from considerable distress. Life review is a process of recalling, evaluating and integrating life experiences to alleviate a sense of despair and achieve self-integrity. Empirical data have supported the fact that life review is an effective psychological intervention, but it is not always accessible to patients with cancer. There is little evidence of internet-based life review programmes tailored to patients with cancer. This study aims to develop a WeChat-based life review programme and evaluate its effectiveness on the psycho-spiritual well-being of patients with cancer undergoing chemotherapy.Methods and analysisA single-centre randomised parallel group superiority design will be used. Patients with cancer will be randomised, to either a control group, or to an experimental group receiving a 6-week WeChat-based life review programme. The programme, which was mainly developed based on Erikson’s psycho-social development theory and Reed’s self-transcendence theory, provides synchronous and asynchronous communication modes for patients to review their life. The former is real-time communication, providing an e-life review interview guided by a facilitator online. The latter is not simultaneously dialogic and is used to interact with patients before and after a life review interview through Memory Prompts, Review Extraction, Mind Space and E-legacy products. The primary outcomes include anxiety, depression and self-transcendence, and the secondary outcomes are meaning in life and hope. These will be measured at baseline, and immediately, at 3 months, and at 6 months after the programme’s conclusion.Ethics and disseminationEthics approval has been obtained from the Biological and Medical Research Ethics Committee of the corresponding author’s university (IRB Ref No: 2016/00020). The trial results will be published in a peer-reviewed journal and presented at national and international conferences.Trial registration numberChiCTR-IOR-17011998.

Background:Biologics have revolutionized the treatment of axial spondyloarthritis (axSpA). However, there is limited knowledge about factors associated with their use in Canada.Objectives:To evaluate sociodemographic, healthcare and patient-reported outcomes (PROs) associated with the use of biologics in Canadian axSpA patients.Methods:The International Map of Axial Spondyloarthritis (IMAS) is a cross-sectional online survey of non-selected patients with self-reported axSpA, conducted in 21 countries and endorsed by the Axial Spondyloarthritis International Federation (ASIF). IMAS captures the patients’ perspective of the burden of axSpA. The Canadian adaptation included a review of the survey by an advisory board of axSpA patients and a national steering committee composed of the Canadian Spondylitis Association, rheumatologists and patients. Participants were recruited between August 2018 and February 2019. Sociodemographic and healthcare-related variables, as well as PROs (disease activity [BASDAI, 0–10], spinal stiffness [3–12], functional limitation [0–54] and psychological distress [GHQ-12]) were collected. Respondents were divided in 2 groups 1) biologic and 2) NSAIDs or no treatment, based on reported pharmacologic treatments. Statistical analyses were performed to assess associations between variables and biologic use (bivariate) and the relative weight of these associations (multivariate).Results:542 axSpA patients were recruited. Mean age was 44.3±13.9 years, 63.1% were female, 66.4% married and 81.0% educated to university/college level. 22.8% of patients lived >50 km from their rheumatologist. Mean BASDAI was 5.3±2.1 and mean GHQ-12 score (mental health) was 4.0±3.8. Nearly half (49.6%) were currently on a biologic. Reported incidence of side effects was lower for patients having biologics (42.5%) vs. a NSAIDs (53.7%) as part of their treatment armamentarium. Only 15.7% of patients had discontinued biologic therapy, the main reasons for withdrawal being physician recommendation (50%), side effects (50%) and personal choice (34%). Variables associated with biologic use included: membership of a patient support group (p<0.001), non-manual work (p=0.008), higher income level (p=0.039), having a combination of public and private insurance schemes (p<0.001) and diagnosis by a rheumatologist (p<0.001). Associated PROs were spinal stiffness (p=0.011) and diagnostic delay (p=0.030). In the multivariate analysis, all variables except income and diagnostic delay were associated with biologic use (Table 1).Table 1.Analysis of sociodemographic and clinical variables in relation to pharmacologic treatmentVariableUnivariate linear regressionMultivariate stepwise linear regressionB95% CIB95% CIIncome level0.0011.000–1.000NANAEmployment—manual worker–0.7610.266–0.822–0.8380.228–0.820Member of a patient support group0.9371.797–3.6281.1161.754–5.309Health insurance scheme—combination0.2091.162–1.3070.2151.132–1.357Diagnostic delay0.0090.993–1.026NANASpinal Stiffness (3–12)0.0991.022–1.1930.2201.090–1.424Diagnosed by rheumatologist0.5351.412–2.0670.3351.041–1.877B, B coefficient; NA, [not applicable]Conclusion:Canadian axSpA patients with greater social status, disease awareness, and insurance options are more likely to receive biologic therapy. Furthermore, Canadian physicians are more inclined to prescribe biologics to patients with increased spinal stiffness.Disclosure of Interests:Robert Inman: None declared, Marco Garrido-Cumbrera: None declared, Jon Chan: None declared, Martin Cohen: None declared, Artur J. deBrum Fernandes: None declared, Wendy Gerhart: None declared, Nigil Haroon: None declared, Algis Jovaisas: None declared, Gerald Major: None declared, Michael Mallinson: None declared, Sherry Rohekar: None declared, Patrick Leclerc Employee of: Novartis, Julie Schneiderman Employee of: Novartis, Proton Rahman Grant/research support from: Janssen and Novartis, Consultant of: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, and Pfizer., Speakers bureau: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, Pfizer

IntroductionChildhood overweight and obesity (OWO) is a primary global health challenge. Childhood OWO prevention is now a public health priority in China. The Sino-Canadian Healthy Life Trajectories Initiative (SCHeLTI), one of four trials being undertaken by the international HeLTI consortium, aims to evaluate the effectiveness of a multifaceted, community-family-mother-child intervention on childhood OWO and non-communicable diseases risk.Methods and analysisThis is a multicentre, cluster-randomised, controlled trial conducted in Shanghai, China. The unit of randomisation is the service area of Maternal Child Health Units (N=36). We will recruit 4500 women/partners/families in maternity and district level hospitals. Participants in the intervention group will receive a multifaceted, integrated package of health promotion interventions beginning in preconception or in the first trimester of pregnancy, continuing into infancy and early childhood. The intervention, which is centred on a modified motivational interviewing approach, will target early-life maternal and child risk factors for adiposity. Through the development of a biological specimen bank, we will study potential mechanisms underlying the effects of the intervention. The primary outcome for the trial is childhood OWO (body mass index for age ≥85th percentile) at 5 years of age, based on WHO sex-specific standards. The study has a power of 0.8 (α=0.05) to detect a 30% risk reduction in the proportion of children with OWO at 5 years of age, from 24.4% in the control group to 17% in the intervention group. Recruitment was launched on 30 August 2018 for the pilot study and 10 January 2019 for the formal study.Ethics and disseminationThe study has been approved by the Medical Research Ethics Committee of the International Peace Maternity and Child Health Hospital in Shanghai, China, and the Research Ethics Board of the Centre Intégré Universitaire de Santé et Services Sociaux de l’Estrie–CHUS in Sherbrooke, Canada. Data sharing policies are consistent with the governance policy of the HeLTI consortium and government legislation.Trial registration numberChiCTR1800017773.Protocol versionNovember 11, 2020 (Version #5).

Background: Severe acute respiratory coronavirus virus 2 (SARS-CoV-2), able to cause pneumonia in humans, was discovered in Wuhan, Hubei Province, China. Investigations related to transmissibility are ongoing, but human-to-human transmission involving healthcare workers providing patient care and close contacts of infected patients have been confirmed. Infection control procedures are necessary to prevent transmission during delivery of health care in healthcare settings. Public health in Canada is a shared responsibility among municipal, provincial, territorial, and federal governments. Significant public health events require coordination between all levels of government and a consistent approach across jurisdictions. The objective of this summary is to describe the Public Health Agency (PHAC)’s Infection Prevention and Control (IPC) guideline on SARS-CoV-2. Methods: The PHAC’s interim guideline for infection prevention and control of 2019-nCoV in acute healthcare settings was informed by the currently limited evidence available, and adapted to the context of healthcare delivery in Canada. The guideline is based upon Canadian guidance developed for previous coronavirus outbreaks (eg, SARS and MERS), as well as the World Health Organization (WHO)’s interim guidance. Technical advice was provided by the National Advisory Committee on Infection Prevention and Control (NAC-IPC) of the Government of Canada. Interjurisdictional collaboration and decision making between multiple authorities and levels of government was facilitated using PHACs federal/provincial/territorial (FPT) Public Health Response Plan for Biological events (Fig. 1). Results: In the absence of effective drugs or vaccines, IPC strategies to prevent or limit SARS-CoV-2 transmission in healthcare settings include the following: prompt identification of signs, symptoms and exposure criteria, implementation of appropriate IPC measures (eg, contact and droplet precautions, patient isolation, N95 respirator plus eye protection when performing aerosol-generating medical procedures on a person under investigation), and etiologic diagnosis. Guideline recommendations are informed by collective expert interpretation of available evidence. Recommendations cover all relevant areas including screening and assessment, public health surveillance and notification, laboratory testing and reporting, respiratory hygiene, hand hygiene, patient placement and flow, management of visitors, use of personal protective equipment, environmental cleaning and discontinuation of precautions. Conclusions: This guideline is an ever-changing document. Changes in recommendations provided may be warranted with new evidence, changes in WHO guidelines, or other identified concerns. FPT governments continue to work collaboratively to ensure that Canada is ready to respond to public health events and is prepared to protect the health of Canadians. Opportunities for international collaboration on IPC products, as well as knowledge exchange and mobilization, continue to thrive.Funding: NoneDisclosures: None

This medal is awarded by the New Zealand Plant Protection Society to honour those who have made exceptional contributions to plant protection in New Zealand in the widest sense. The medal is awarded for outstanding services to plant protection, whether through research, education, implementation or leadership. In 2017, the New Zealand Plant Protection Medal was awarded Prof David Maxwell (Max) Suckling. In his 35+ years of research, Max has been pivotal in bringing odour-based technologies to New Zealand. In particular, his research on insect pheromones has enabled integrated pest management to be realised in this country. As a result, New Zealand plant-based industries can access premium overseas markets due to the low pest prevalence and low pesticide residue on primary produce. It has also reduced grower exposure to pesticides. The acknowledgement of his broad knowledge of risks and benefits that new organisms and substances can pose to New Zealand has been exemplified by his position of Chair of the Environmental Risk Management Authority Hazardous Substances and New Organisms Committee where he presided over decisions from determining which organisms are new to New Zealand through to whether the benefits of the release of new organisms outweighed the risks. His unique knowledge and ability to make sound judgements based on the evidence presented also led to two invitations back to the Environmental Protection Authority after he had finished as a special member on the Committee so that New Zealand could safely continue to assess the use of biological control agents. Since 2004, in his role as Science Group Leader of the Biosecurity group at The New Zealand Institute for Plant and Food Research Ltd (PFR), Max has been instrumental in developing tools to improve detection sensitivity and socially acceptable eradication options for new pests that threaten New Zealand, such as the Queensland fruit fly and the painted apple moth. Max has been a member of the New Zealand Plant Protection Society for many years and served as President from 1999 to 2001. He was nominated for the Medal because of the passion he has displayed towards developing and making available socially acceptable pest eradication and management tools in New Zealand. The work that he and the chemical ecology team he has built and led, has had a large impact in many sectors from horticulture to biosecurity. This use of socially acceptable tools for the productive sectors naturally led to Max’s involvement in the pest surveillance and eradication space. He led the Eradication and Response Theme in the Better Border Biosecurity collaboration for over ten years, co-ordinating research among Crown Research Institutes to achieve their goals and the goals of New Zealand’s biosecurity practitioners. He has gone beyond odour-based technologies and branched into sound, vision and sterile-insect technologies for managing pests, sticking with the social acceptance theme. Max is an innovative thinker, testing novel approaches for pest management, and can bring quite separate groups together to achieve a goal. For example, he combined an irradiator used to sterilise medical equipment and insect rearing to achieve a boutique insect-sterilisation programme against the painted apple moth. By pushing the envelope, he is seen as a world leader in his field of using socially acceptable tools, with numerous invitations as a keynote speaker at international meetings, which has allowed him to return to New Zealand with some of the latest scientific ideas. He has served on working groups of the sterile-insect technique for the joint division of the Food and Agriculture Organization/International Atomic Energy Agency. He was recently made a professor when he was made a joint appointment at PFR and the University of Auckland, and has supervised and co-supervised a number of PhD and MSc students. His outstanding collaboration and mentoring skills enable him to work across different fields, secure new knowledge and tools for novel pest-management approaches, bring together people from different organisations, and mentor ‘thinking-out-of-the-square’ scientists for the future. His desire to protect New Zealand’s flora, fauna and people, make him a worthy recipient of the New Zealand Plant Protection Medal. NZPP Medal recipients for the previous five years: 2016: Rob Beresford 2015: Gary Barker 2014: - 2013: Andrew Hodson 2012: Margaret Dick

BackgroundThe conventional frontline therapy for fit patients with chronic lymphocytic leukaemia (CLL) is fludarabine, cyclophosphamide and rituximab (FCR). Rituximab (Mabthera®, Roche Products Ltd) targets the CD20 antigen, which is expressed at low levels in CLL. The standard dose of rituximab in CLL (375 mg/m2in cycle 1 and 500 mg/m2in cycles 2–6) was selected based on toxicity data only. Small doses of rituximab (as low as 20 mg) have biological activity in CLL, with an immediate reduction in circulating CLL cells and down-regulation of CD20. Phase II trials had suggested improved efficacy with the addition of mitoxantrone to FCR. The key assumption for the Attenuated dose Rituximab with ChemoTherapy In CLL (ARCTIC) trial was that the addition of mitoxantrone to fludarabine, cyclophosphamide and low-dose rituximab would be more effective than conventional FCR.ObjectivesTo assess whether fludarabine, cyclophosphamide, mitoxantrone and low-dose rituximab (FCM-miniR) (100 mg of rituximab per cycle) was non-inferior to FCR in frontline CLL. Complete response (CR) rate was the primary end point, with the secondary end points being progression-free survival (PFS), overall survival (OS), overall response rate, eradication of minimal residual disease (MRD), safety and cost-effectiveness.DesignARCTIC was a UK multicentre, randomised, controlled, open, Phase IIB non-inferiority trial in previously untreated CLL. A total of 206 patients with previously untreated CLL who required treatment, according to the International Workshop on Chronic Lymphocytic Leukaemia criteria, were to be randomised to FCR or FCM-miniR. There was an independent Data Monitoring and Ethics Committee (DMEC) with a pre-planned interim efficacy assessment on 103 participants.ResultsThe DMEC’s interim analysis led to early trial closure. Although the response rates in both arms were higher than anticipated, FCM-miniR had a lower CR rate than FCR. This was partly attributable to the higher toxicity associated with mitoxantrone. A total of 100 participants completed FCR, 79 completed FCM-miniR and 21 commenced FCM-miniR but switched to FCR following DMEC recommendations. The CR rate for participants receiving FCR was 76%, compared with 55% for FCM-miniR (adjusted odds ratio 0.37; 95% confidence interval 0.19 to 0.73). Key secondary end points also showed that FCR was superior, with more participants achieving MRD negativity (57% for FCR vs. 46% for FCM-miniR). More participants experienced a serious adverse reaction with FCM-miniR compared with FCR (50% vs. 41%). At a median of 37.3 months’ follow-up, the PFS and OS rates are good compared with previous studies, with no significant difference between the treatment arms. The economic analysis indicates that because FCM-miniR is less effective than FCR, FCM-miniR is not expected to be cost-effective over a lifetime horizon, producing a mean cost-saving of –£7723, a quality-adjusted life-year loss of –0.73 and a resulting incremental net monetary loss of –£6780.ConclusionsFCM-miniR is less well tolerated, with poorer response rates, than FCR, partly owing to the additional toxicity associated with mitoxantrone. In view of this, FCM-miniR will not be taken forward into a larger definitive Phase III trial. The trial demonstrated that oral FCR yields extremely high response rates compared with historical series with intravenous chemotherapy.Future workWe shall compare the results of ARCTIC with those of the ADMIRE (Does the ADdition of Mitoxantrone Improve Response to FCR chemotherapy in patients with CLL?) trial, which compared FCR with FCM-R to assess the efficacy of low- versus standard-dose rituximab, allowing for the toxicity associated with mitoxantrone.Trial registrationCurrent Controlled Trials ISRCTN16544962.FundingThis project was funded by the NIHR Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 21, No. 28. See the NIHR Journals Library website for further project information.

At the present stage, the development of dairy farming needs to focus on increasing the livestock population with high productive indicators in the large-scale sector. In the period from 2000 to 2020, the number of cows in Ukraine decreased by 2.8 times (from 4958.3 thousand heads on 01.01.2001 to 1788.5 thousand heads on 01.01.2020), and in agricultural enterprises – by 4.2 times (from 1851.0 to 438.6 thousand heads respectively). An important factor in the growth of the large-scale sector should be the revival of the national selection system. Therefore, the issue of scientific substantiation of the organizational principles of effective management of breeding dairy cattle breeding is now of particular urgency. The purpose of the article is to carry out an evaluation of genetic resources of breeding dairy cattle Ukraine. The research was conducted on the observation materials of the State Statistics Service of Ukraine, the International Committee for Animal Recording, the State Register of subjects of breeding business in livestock breeding by using statistical methods. Cattle breeds are differ according to economic indicators of useful traits of animals, including the level of productivity, which significantly influences the economic efficiency of production. According to ICAR (The International Committee for Animal Recording), cows of the Holstein breed remain the leaders, whose productivity for the 305 days of lactation is at the level of 9–11 thousand kg of milk. Such achievements are the result of a long intensive breeding work aimed at increasing milk production. Among other breeds, which cow' productivity approachs the animals Holstein breed, Ayrshire (up to 9.0 thousand kg), Braunvieh, Montbeliarde, Fleckvieh, Norwegian Red, Swedish Red, Jersey (7.0–8.0 thousand kg) are next. A number of breeds are distinguished by qualitative features of dairy productivity. For example, the fat content in milk of cows of the Jersey breed of Canadian breeding is 5.1%. The milk productivity of these breeds is lower than Holstein dairy cows. But they have significant benefits in functional traits such as high reproductive capacity, extended duration of economic use, high payment of feed by the resulting products, which increases their competitiveness to the level of animals of the Holstein breed. In Ukraine, the highest milk productivity is Holstein (8965 kg), Fleckvieh (8877 kg), Ukrainian Black and White Dairy (7486 kg) and Ukrainian Red and White Dairy (6997 kg). Currently, in 344 breeding herds, 137.8 thousand cows are kept, which is one third less than 10 years ago. The most numerous is the Ukrainian Black and White Dairy – 68.829 purebred cows, or 49.9% in the structure of dairy cattle breeding herds. The share of Holstein – 25.2%, Ukrainian Red and White Dairy is 14.4%. It should be noted the extremely insufficient number of cows of the active part of the livestock (breeding stock-rearing farms that are certified as subjects of the tribal affairs and conduct breeding records) – 29.5% of the number of cows kept in agricultural enterprises, and 7.7% – at farms all categories. For example, in Israel (the world leader in the cows’ milk productivity in level about 12 thousand kg per cow) it is more than 90%. In other countries with a developed dairy industry, this figure is at 90% – in Denmark, 86% in Sweden, and 70% in Canada. The low proportion of the recorded dairy livestock in Ukraine greatly complicates the process of improving high-yielding herds. Over the past ten years, the number of breeding stock-rearing farms in Ukraine has doubled. Among them there was a tendency for livestock consolidation. Average number of cows in herds the breeding stock-rearing farms was: in 2007 – 241 heads, in 2012 – 334, in 2017 – 373, in 2019 – 401. In 2007–2019, as a result of ongoing concentrations of livestock, the average size of a purebred dairy herd increased almost one and a half times, which, due to the scale effect, made it possible for enterprises to reduce production costs per unit. The average milk yield of purebred cows in industrial enterprises increased from 4606 kg in 2007 to 7653 kg in 2019, or almost one and a half times. Due to the effect of the factor of natural biological antagonism on the milk productivity and reproductive capacity of cows, the raising of productivity with an increase in the heredity of the Holstein breed has led to a decrease in the calving output of 100 cows, and a decrease in the length of the commercial use of cows. This trend is also characteristic of all newly created dairy breeds. In particular, from Ukrainian Black and White Dairy cows the calving output per 100 cows decreased from 82.8 heads in 2006 to 77.4 in 2019; Ukrainian Red and White Dairy respectively from 82.2 to 69.5 calves; Ukrainian Red Dairy, where the proportion of the heredity of the Holstein breed is slightly lower than the first two, the calving rate dropped at lower pace. According to the results of dairy cattle recording, among the domestic breeds the highest milk productivity is in the Ukrainian Black and White Dairy cows – 7364 kg with a fat content of 3.74%, protein 3.22%; Ukrainian Red and White Dairy – respectively 6989; 3.78; 3.27; Ukrainian Red Dairy – 6549; 3.90; 3.26. Domestic breeds on genetic potential are at the level of the best European analogues, and according to indicators of reproduction and health they prevail them. Consequently, the breed of cows is an important factor in the economic efficiency of dairy cattle-breeding. Due to the long intensive selection work on cattle breeds, the milk productivity of cows in developed livestock countries has reached levels of 8.0–10.0 thousand kg and more for 305 days of lactation. The number of cows in breeding farms in Ukraine for 2006–2019 has decreased by 38 thousand head, or by 22%. The average milk yield of purebred cows in industrial enterprises increased from 4606 kg in 2007 to 7653 kg in 2019, or almost one and a half times. But the extremely insufficient number of cows of the active part of the livestock greatly complicates the process of improving high-yielding herds. In the breeding structure of pedigree dairy cattle, animals of Ukrainian Black and White Dairy (49.9%), Holstein breeds (25.2%) and Ukrainian Red and White Dairy (14.4%) prevail.